Jump to content

Corneal cross-linking: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
PrimeBOT (talk | contribs)
Bots
2,042,997 edits
m →References: rmv template being deleted - TFD - BRFA
Line 70: Line 70:
* [http://www.nkcf.org/corneal-collagen-cross-linking/ Corneal Collagen Cross-Linking] on National Keratoconus Foundation website.
* [http://www.nkcf.org/corneal-collagen-cross-linking/ Corneal Collagen Cross-Linking] on National Keratoconus Foundation website.
* [http://eyewiki.aao.org/Corneal_Collagen_Cross-Linking Corneal Collagen Cross-Linking] on [[EyeWiki]] from the [http://www.aao.org American Academy of Ophthalmology]
* [http://eyewiki.aao.org/Corneal_Collagen_Cross-Linking Corneal Collagen Cross-Linking] on [[EyeWiki]] from the [http://www.aao.org American Academy of Ophthalmology]
* [https://www.keratoconusgroup.org/2017/06/corneal-crosslinking-coverage-in-the-united-states.html Insurance coverage of cross-linking for keratoconus] (United States, May 2017)


{{Eye surgery}}
{{Eye surgery}}

Revision as of 18:41, 10 June 2017

Corneal cross-linking
Cross-linking procedure, UV light source[1]
Other namescross-linking, CXL, C3-R, CCL, KXL
CPT0402T

Corneal collagen cross-linking with riboflavin (vitamin B2) and UV-A light is a surgical treatment for corneal ectasia such as keratoconus, PMD, and post-LASIK ectasia.

It is used in an attempt to make the cornea stronger. According to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus.[2] In 2016, the US Food and Drug Administration approved riboflavin ophthalmic solution crosslinking based on three 12-month clinical trials.[3]

Medical uses

A 2015 Cochrane review that looked at all high quality evidence on corneal collagen cross-linking found that it was insufficient to determine if it is useful in keratoconus.[2]

Adverse effects

Among those with keratoconus who worsen CXL may be used. In this group the most common side effects are haziness of the cornea, punctate keratitis, corneal striae, corneal epithelium defect, and eye pain. In those who use it after post-LASIK ectasia, the most common side effects are haziness of the cornea, corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, and sensitivity to bright lights.[4]

There are no long term studies about crosslinking effect on pregnancy and lactation. According to a manufacturer crosslinking should not be performed on pregnant women.[4]

Cautions

People undergoing crosslinking should not rub their eyes for the first five days after the procedure.[4]

Procedure

Removed corneal epithelium during CCR operation on an eye with post-LASIK complication, from Kymionis et al., 2009[5]

Corneal cross-linking involves application of riboflavin solution to the eye that is activated by illumination with UV-A light for approximately 30 or less minutes. The riboflavin causes new bonds to form across adjacent collagen strands in the stromal layer of the cornea, which recovers and preserves some of the cornea's mechanical strength. The corneal epithelial layer is generally removed to increase penetration of the riboflavin into the stroma, a procedure known as the standard protocol.[6]

People that are considered for treatment must undergo an extensive clinical workup, including corneal tomography, computerized corneal topography, endothelial microscopy, ultrasound pachymetry, b-scan sonography, keratometry and biomicroscopy.

History

The technique was first developed in Germany in 1997 by Eberhard Spoerl and his team at the Dresden University of Technology.[7][8][third-party source needed]

Approvals and clinical trials

In Germany clinical trials have been in course since 1998.[7] in Italy routine interventions have been successfully performed since 2005.[9] The standard protocol of Corneal Collagen Cross-linking, with epithelium removal, is approved for use throughout Europe.

In the United States clinical trials commenced only in 2008. based on three 12-month clinical trials, the US Food and Drug Administration approved riboflavin ophthalmic solution and KXL system for crosslinking on April 18, 2016, for the treatment of progressive keratoconus, and on July 19, 2016, for corneal ectasia after refractive surgery, making them the first FDA approved treatment for keratoconus and post-LASIK ectasia.[3][10]

Research

As of 2016 research was ongoing.[11]

Transepithelial or epithelium-on (epi-on) cross-linking is a technique which was first performed in 2004 in the U.S.,[12] the corneal epithelium layer is left intact.[13] in this technique, because the epithelium is not removed, riboflavin loading requires more time than with epi-off techniques, and may be less effective.[14]

In a "pocket cross-linking" procedure, riboflavin is injected directly into the corneal stroma via a corneal pocket in order to bypass the epithelium, which is left intact.[15][16]

Contact lens-assisted cross-linking (CACXL) may be performed for people with corneal stromal thickness between 350 µm to 400 µm after epithelial removal. in this method a pre-corneal riboflavin film, a riboflavin-soaked UV barrier-free soft contact lens of negligible power and a pre-contact lens riboflavin film are used to decrease UV irradiance to safe levels at the level of the endothelium.[17][18]

Topography-guided crosslinking relies on an active eye tracker to allow a patterned delivery of UV light. Both the power and pattern can be programmed into the unit based on the topography of the individual's eyes.[19]

Accelerated crosslinking would allow a shorter treatment time by delivering more energy, compared to the standard crosslinking procedure, which involves 3 mW of UVA exposure for 30 minutes.[19]

References

  1. ^ Renesto Ada, C; Sartori, M; Campos, M (January–February 2011). "[Cross-linking and intrastromal corneal ring segment]". Arquivos brasileiros de oftalmologia. 74 (1): 67–74. doi:10.1590/s0004-27492011000100017. PMID 21670914.
  2. ^ a b Sykakis, E; Karim, R; Evans, JR; Bunce, C; Amissah-Arthur, KN; Patwary, S; McDonnell, PJ; Hamada, S (24 March 2015). "Corneal collagen cross-linking for treating keratoconus". The Cochrane database of systematic reviews. 3: CD010621. doi:10.1002/14651858.CD010621.pub2. PMID 25803325.
  3. ^ a b Lowes, Robert (18 April 2016). "FDA Approves Photrexa for Corneal Crosslinking in Keratoconus". Medscape.com.
  4. ^ a b c "PHOTREXA VISCOUS- riboflavin 5-phosphate in 20% dextran ophthalmic solution/ drops PHOTREXA- riboflavin 5-phosphate ophthalmic solution/ drops". DailyMed. U.S. NATIONAL LIBRARY OF MEDICINE.
  5. ^ Kymionis GD, Diakonis VF, Coskunseven E, Jankov M, Yoo SH, Pallikaris IG (2009). "Customized pachymetric guided epithelial debridement for corneal collagen cross linking". BMC Ophthalmology. 9: 10. doi:10.1186/1471-2415-9-10. PMC 2744909. PMID 19715585.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. ^ Spoerl E, Wollensak G, Dittert DD, Seiler T (2004). "Thermomechanical behavior of collagen-cross-linked porcine cornea". Ophthalmologica. 218 (2): 136–40. doi:10.1159/000076150. PMID 15004504.
  7. ^ a b SPOERL, EBERHARD; HUHLE, MICHAEL; SEILER, THEO (January 1998). "Induction of Cross-links in Corneal Tissue". Experimental Eye Research. 66 (1): 97–103. doi:10.1006/exer.1997.0410.
  8. ^ Spörl, E; Seiler, T; Huhle, M; Kasper, M (1997). "Increased rigidity of the cornea caused by intrastromal cross-linking". Ophthalmologe. 94: 902–6. doi:10.1007/s003470050219. PMID 9487761.
  9. ^ Caporossi, Aldo; Mazzotta, Cosimo; Baiocchi, Stefano; Caporossi, Tomaso (April 2010). "Long-term Results of Riboflavin Ultraviolet A Corneal Collagen Cross-linking for Keratoconus in Italy: The Siena Eye Cross Study". American Journal of Ophthalmology. 149 (4): 585–593. doi:10.1016/j.ajo.2009.10.021.
  10. ^ "Highlights of Prescribing Information: PHOTREXA VISCOUS (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% for topical ophthalmic use PHOTREXA (riboflavin 5'-phosphate ophthalmic solution) 0.146% for topical ophthalmic use For use with the KXL® System" (PDF). U.S. Food and Drug Administration. pp. 5–14.
  11. ^ "Facts About the Cornea and Corneal Disease". NEI. May 2016. Retrieved 6 November 2016.
  12. ^ Kathryn M. Hatch; William B. Trattler. (16 May 2012). "Corneal Crosslinking: Epi-on or Epi-off?". Medscape.
  13. ^ Spadea, Leopoldo; Mencucci (November 2012). "Transepithelial corneal collagen cross-linking in ultrathin keratoconic corneas". Clinical Ophthalmology: 1785. doi:10.2147/OPTH.S37335.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  14. ^ Shalchi, Z; Wang, X; Nanavaty, M A (3 October 2014). "Safety and efficacy of epithelium removal and transepithelial corneal collagen crosslinking for keratoconus". Eye. 29 (1): 15–29. doi:10.1038/eye.2014.230.
  15. ^ Daxer A, Mahmoud H, Venkateswaran RS (2010). "Corneal Crosslinking and Visual Rehabilitation in Keratoconus in One Session without epithelial debridement: New Technique". Cornea. 29: 1176–1179. doi:10.1097/ico.0b013e3181d2c644.
  16. ^ Studeny P, Krizova D, Stranak Z. "Clinical outcomes after Complete Intracorneal Ring Implantation and Corneal Crosslinking in an Intrastromal Pocket in One Session for Keratoconus". Journal of Ophthalmology. 2014: S1. doi:10.1155/2014/568128.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  17. ^ Agarwal, Amar; Jacob, Soosan (10 August 2014). "Contact lens-assisted cross-linking treats corneal ectatic disorders in thin corneas". Ocular Surgery News U.S. Edition.
  18. ^ Jacob, Soosan. "Contact Lens-Assisted CXL for Thin Corneas". Cataract & Refractive Surgery Today.
  19. ^ a b HERSH, PETER. "Corneal collagen crosslinking: A clinical update".
Wikimedia Commons has media related to corneal collagen crosslinking.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Corneal_cross-linking&oldid=784930525"